Conclusions Blood pressure lowering is an effective strategy for
preventing cardiovascular events among people with moderately reduced
eGFR. There is little evidence from these overviews to support the
preferential choice of particular drug classes for the prevention of
cardiovascular events in chronic kidney disease.